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Abstract 
Hybrid nanoparticles (HNPs) have shown huge potential as drug delivery vehicles for 
pancreatic cancer. Currently, the first line treatment, gemcitabine, is only effective in 
23.8% of patients. To improve this, a thermally activated system was developed by 
introducing a linker between HNPs and gemcitabine. Whereby, heat generation 
resulting from laser irradiation of the HNPs promoted linker breakdown resulting in 
prodrug liberation. In vitro evaluation in pancreatic adenocarcinoma cells, showed the 
prodrug was 4.3 times less cytotoxic than gemcitabine, but exhibited 11-fold 
improvement in cellular uptake. Heat activation of the formulation led to a 56% rise 
in cytotoxicity causing it to outperform gemcitabine by 26%. In vivo the formulation 
outperformed free gemcitabine with a 62% reduction in tumor weight in pancreatic 
xenografts. This HNP formulation is the first of its kind and has displayed superior 
anti-cancer activity as compared to the current first line drug gemcitabine after heat 
mediated controlled release.  
 
 
Keywords: Pancreatic cancer, Gemcitabine, Hybrid nanoparticle, Thermo-responsive 
drug delivery, Diels Alder 
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Introduction 
Pancreatic cancer has a 5-year survival rate after diagnosis of 3.7 % [1-3]. This 
particularly deadly type of cancer has the worst prognosis of all cancer types [4-6]. It 
is the 5th most common cause of cancer death in the UK [7] and 4th most common in 
the US [8,9]. It occurs in only 2.6 % of all cancer cases as of 2011, but is responsible 
for 5.2 % of cancer deaths in the UK, which is a significantly disproportionate 
survival statistic owing to its poor prognosis. Its 5-year survival rate has only 
increased from 2 % to 3.7 % on average since 1975. These statistics show the 
deadliness and great importance in improving the survival rates of those who are 
diagnosed with pancreatic cancer. Surgery is the only method capable of curing 
pancreatic cancer and is often accompanied by post-operative chemotherapy to reduce 
the chances of recurrence [10]. Even after early detection, subsequent surgery and 
post-operation chemotherapy the survival rate only increases to 21 % [4,10]. A 
contributing reason for this is because pancreatic cancer rarely causes noticeable 
symptoms primarily attributed to cancer until it is fairly advanced and has spread to 
surrounding tissues [11]. Once this has occurred, surgery is no longer an option and 
patient quality of life becomes the top priority [12]. 
 
In most cases of pancreatic cancer, gemcitabine (GEM) is given as a first line 
chemotherapy because it demonstrates therapeutic efficacy in halting tumor growth 
[13]. Even with the increased survival rate with GEM the prognosis for pancreatic 
cancer is still abysmal, as such urgent improvements and novel strategies in 
pancreatic cancer chemotherapeutics are needed. GEM has a response rate of 23.8 % 
which means that 76.2 % of patients taking GEM see no viable response to the drug 
[14,15]. GEM is an aggressively toxic compound which indiscriminately targets both 
cancerous and non-cancerous cells leading to the side effects associated with 
chemotherapy such as hair loss, nausea and fatigue [8,16]. It possesses low efficacy 
meaning that most of the drug is metabolised and excreted before being able to carry 
out its intended pharmaceutical activity. Even with significant cytotoxic effects, it s 
dosage must be as high as possible to ensure that enough pharmaceutical activity at 
the site of action occurs, due to its poor biocompatibility. Its small molecular weight 
contributes to its rapid renal clearance. Combating this clinically involves providing 
frequent high doses of the drug which can cause hepatic and renal toxicity [17]. In 
order to improve patient outcomes, three major issues need to be addressed. These 
are: 1) lack of early diagnosis and lag time before treatment, 2) lack of drug 
permeability through the dense stroma in these tumors and 3) lack of drug specificity. 
This work aims to overcome these challenges by the development of nanoparticles 
with the capability for image guidance, targeting, deep penetration, and controllable 
drug release. Development of such platforms will form rapid and effective treatments 
which will result in improved patient prognosis. 
 
Using model drug molecules, we have shown that after either incorporation onto / into 
nanoparticles [19,20], or drug encapsulation into polymeric micelles [21], consistently 
increased drug uptake is achieved in vitro in pancreatic cancer cells. Additionally, in 
vivo in pancreatic xenograft models, we have shown that after delivery in a 
nanoparticle formulation, drug molecules are significantly more capable of tumor 
retardation compared with free drug molecules [14]. 
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Nano-sized formulations of cytotoxic agents have been proven to passively target 
cancerous tissue and promote increased drug efficacy via the enhanced permeability 
and retention effect (EPR). However, pancreatic adenocarcinoma is characterised by 
dense solid tumours, which reportedly do not allow for EPR accumulation [22-24]. As 
such, other mechanisms of drug targeting to the site of action such as active targeting 
with site specific ligands or local administration must be considered. 
We have fabricated HNPs and demonstrated their potential for imaging using 
magnetic resonance imaging [25], heating after laser irradiation (by exploitation of 
surface plasmon resonance) in phantoms that mimic biological systems [26], in vitro 
[27] and in vivo [19]. We have also reported the use of these HNPs as drug carrier 
vehicles [28] and have demonstrated their utility as heat initiated drug release vehicles 
[19]. These systems confer highly controllable drug delivery and can be utilised in 
image guided stimuli-responsive drug delivery or used as theranostic agents. 
Recently, the use of HNPs as heat triggered vehicles for drug delivery by exploiting 
reversible electrostatic binding of charged drug molecules onto the surface of the 
hybrid nanoparticles was reported [19]. The study trialled novel bisnaphthalamide 
based drug compounds which had shown previous potential in cancer therapy. 
Significant drug release was observed at temperatures above 44 ˚C. In vivo evaluation 
after intra-tumoral (I.T.) administration to pancreatic xenograft models in nude mice 
resulted in 5-fold tumor retardation after heat initiation promoting drug release [19].  
Recently, a growing trend in cancer therapeutics is to try and overcome side effects 
associated with systemic therapies. For many drug molecules and nanotechnology in 
specific, the main problem is the accumulation in the liver after IV administration and 
associated metabolic breakdown. Hence, a growing trend is to directly administer 
these potent compounds directly to the tumor site (I.T.). In fact, in 2017 reports have 
shown that nanoparticles [19, 29], microparticles [30], and peptides [31] have been all 
been administered via this route with a clinical trial in pancreatic cancer being 
outlined by Hajda et al. [32]. Multiple studies have been reported for the use of laser 
activated systems for either triggered drug release or for ablation in cancer therapy 
[19,33,34]. For the most, these systems rely on the use of minimally invasive surgery 
in order for the laser to access its destination due to limited penetration depths. Here, 
we proposed an I.T. administered formulation which then undergoes laser activation. 
Hence, since laser irradiation requires minimally invasive surgery, I.T. injection will 
be appropriate. In the case of pancreatic cancer, the patient prognosis is so bad that 
minimally invasive surgery is a viable option in order to prolong life. 
This study aims to conjugate GEM onto the surface of HNPs in order to determine 
whether such coupling could increase drug efficacy in the solid tumors formed in 
vivo. Unfortunately, the physicochemical properties of GEM do not allow for 
electrostatic interaction with the HNP surface. As such a Diels Alder linker will be 
employed to conjugate the drug molecules onto the surface (Figure 1). By exploiting 
the thermal reversibility of Diels Alder cycloadducts, the thermal release of drug 
compounds can be initiated due to heat generation after laser irradiation of the HNPs 
via the surface plasmon resonance. Here we report the synthesis and evaluation of 
HNP-L-GEM both in vitro and in vivo for use as a heat triggered carrier for the 
precision treatment of pancreatic cancer. 
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Figure 1. Schematic representation of mechanism of drug loading/release from the hybrid 
nanoparticle surface via heat initiated reversal of the Diels Alder reaction. 
 
Methods 
All chemicals were purchased from Alfa Aesar, UK unless otherwise stated and were 
at least ACS reagent grade or greater purity. Gemcitabine was purchased from 
Fluorochem, UK and was analytically pure. HPLC grade organic solvents used for 
chemical synthesis and analysis were purchased from Fisher Scientific, UK. 
Deuterated solvents were purchased from Cambridge Isotope Laboratories, USA. 
Visking membrane was purchased from Medicell, UK. Human pancreatic 
adenocarcinoma (BxPC-3) cells were purchased from ATCC, USA. Cell culture 
media and consumables were purchased from Fisher Scientific, UK. 
 
Synthesis of L-GEM 
1H NMR spectra were recorded at 300 MHz using a Bruker Spectrospin DPX 300 
Spectrometer. All NMR samples were made up in deuterated solvents with all values 
quoted in ppm relative to tetramethylsilane (TMS) as an internal reference. Coupling 
constants (J values) are reported in Hertz (Hz). 
Maleic anhydride (0.98 g, 10 mmol) was dissolved in glacial acetic acid (20 mL) 
followed by γ-aminobutyric acid (1.03 g, 10 mmol). The mixture was vigorously 
stirred resulting in a slurry, which was stirred for a further 8 h at room temperature 
under a N2 atmosphere. The white precipitate was collected by filtration and washed 
with water (20 mL × 2). The white solid was then dispersed in 20 mL of water and 
refluxed at 110 °C. Once a clear solution had formed, the mixture was further 
refluxed for an additional 30 min. The solution was left to cool before the water was 
evaporated off. A white precipitate formed which was filtered and washed with 
chilled water. The resultant white powder was then dried in vacuo. 4-
maleimidobutyric acid [Compound 1] was obtained as a white powder (1.72 g, 94 % 
yield) [35]. Compound 1 1H NMR (SI-Figure 1): 6.03 (singlet, [5, 6] 2H), 2.81 
(triplet, [4], 2H), 2.33 (triplet, J=7.3Hz [3], 2H), 1.74 (quintet, J=7.4Hz [2], 2H).  
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Di-tert-butyl dicarbonate (4.36 g, 20 mmol) was dissolved in 1,4 dioxane (40 mL) and 
the solution added dropwise to a stirred solution of gemcitabine hydrochloride (0.60 
g, 2 mmol) in 1M aqueous potassium hydroxide (40 mL) over a period of 10 min. The 
mixture was stirred for 40 min at room temperature and monitored closely using thin-
layer chromatography (TLC). After TLC confirmed the presence of a 50:50 mixture 
of the desired product with 3′-O-bis (tert-butoxycarbonyl) gemcitabine, the reaction 
mixture was extracted with ethyl acetate (80 mL × 3), the organic extracts washed 
with brine (20 mL × 2) and dried over magnesium sulfate. The mixture was then 
filtered and the filtrate was evaporated in vacuo to give a clear oily residue. The 
residue was dissolved in 1,4 dioxane (40 mL) and a solution of di-tert-butyl 
dicarbonate (4.36 g, 20 mmol) in 1M aqueous potassium hydroxide (40 mL). The 
mixture was stirred at room temperature and monitored by TLC. After TLC analysis 
confirmed that all 3′-O-bis(tert-butoxycarbonyl)gemcitabine had been consumed the 
reaction mixture was extracted with ethyl acetate (80 mL × 3), combined, washed 
with brine (20 mL × 2) and dried over magnesium sulfate. The mixture was then 
filtered and the filtrate was evaporated in vacuo to give a pale yellow oily residue. 
3′,5′-O-Bis(tert-butoxycarbonyl)gemcitabine [Compound 2] was obtained as a 
colourless solid (0.326g, 63 %) after column chromatography using a 1:1 mixture of 
acetone:dichloromethane as eluent [36].  Compound 2 1H NMR (SI-Figure 2): 7.61 
(doublet J=7.5Hz [6], 1H), 6.35 (doublet [7], 1H), 5.95 (singlet J=7.5Hz [5] 1H), 5.3 
(singlet [4], 1H), 4.52, 4.46 (multiplet [3], 2H), 4.42 (doublet [2], 1H), 1.5 (single t 
[9], 9H), 1.48 (singlet [8], 9H).  
 
Maleic anhydride (2.9 g, 29 mmol) was dissolved in anhydrous dimethylformamide 
(35 mL). 4-aminobutyric acid (2.68 g, 26 mmol) was added to the solution and the 
mixture was stirred under an argon atmosphere at room temperature. After 3 h the 
mixture was cooled to 0 °C for 0.5 h. N-hydroxysuccinimide (3.7 g, 32 mmol) and 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide (11 g, 71 mmol) were added to the 
mixture. The mixture was stirred at 0 °C for 30 min before being allowed to warm to 
room temperature. The mixture was then stirred overnight at room temperature. The 
solvent was evaporated and the residue was dissolved in chloroform (300 mL). The 
organic solution was washed with saturated sodium bicarbonate (100 mL) and dried 
over magnesium sulfate. The mixture was filtered and the filtrate was evaporated to 
yield a dark green film. The N-hydroxysuccinimide ester of 4-aminobutyric acid 
[Compound 3] was obtained as a colourless powder (4.8 g, 66 %) after column 
chromatography using a 10:1 mixture of chloroform:methanol as eluent [35]. 
Compound 3 1H NMR (SI-Figure 3): 7.01 (singlet [6, 7], 2H), 3.48 (triplet J=7.0Hz 
[2], 2H), 2.80 (singlet [4, 5], 4H), 2.72 (triplet J=7.4Hz [3] 2H), 1.83 (quintet J=7.2Hz 
[1] 2H).  
 
2-Furanmethane thiol (1.00 g, 8.9 mmol) and di-tert-butyl dicarbonate (1.80 g, 8.9 
mmol) were dissolved in anhydrous acetonitrile (35 mL). Anhydrous potassium 
carbonate (2.4 g, 17.5 mmol) was added and the mixture was stirred at room 
temperature for 24 h under a N2 atmosphere. The mixture was diluted with ethyl 
acetate (200 mL) and filtered with the aid of celite. The filtrate was washed with 
saturated sodium bicarbonate solution (40 mL) and dried over magnesium sulfate. 
The mixture was filtered and the filtrate was evaporated to give O-tert-butyl-S-(furan-
2-ylmethyl)carbonothionate [Compound 4] as a brown oil (1.76 g, 93 %) [37]. 
Compound 4 1H NMR (SI-Figure 4): 7.34 (multiplet [3], 1H), 6.3 (multiplet [1], 1H), 
6.23 (multiplet J=3.2Hz [2], 1H), 4.06 (singlet [4] 2H), 1.5 (singlet [5] 9H).  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
  
O-tert-butyl-S-(furan-2-ylmethyl)carbonothionate [Compound 4] (1.5 g, 9 mmol) was 
added into a sealed tube followed by diethyl ether (35 mL). The N-
hydroxysuccinimide ester of 4-aminobutyric acid [Compound 3] (2.4 g, 9 mmol) was 
added and the mixture was stirred at room temperature for 7 days under a N2 
atmosphere. The protected cycloadduct [Compound 5] was obtained as a brown solid 
(2.14 g, 48.3 % yield) after column chromatography using a 1:1 mixture of petroleum 
ether (bpt 40-60 °C): ethyl acetate as eluent. Compound 5 1H NMR (SI-Figure 5):  
6.53 (multiplet [4-endo], 1H), 6.41 (multiplet J=3.2Hz [4-exo], 1H), 6.31 (multiplet 
[3-endo] 1H), 6.24 (multiplet [3-exo] 1H), 5.24 (doublet J=1.7Hz [2], 1H), 4.06 
(singlet [11] 2H), 3.61 (triplet [7], 2H), 3.59 (multiplet J=6.2Hz [1-endo], 1H), 3.44 
(doublet J=6.2Hz [5-endo], 1H), 3.01 (singlet [1-exo] 1H), 2.95 (doublet [5-exo] 1H), 
2.84 (singlet [9,10] 4H), 2.64 (triplet [8], 2H), 2.01 (quintet [6], 2H), 1.5 (singlet [12], 
9H).  
 
The cycloadduct [Compound 5] (3.94 g, 8.2 mmol) was dissolved in dry 
dichloromethane (30 mL). 3′, 5′-O-Bis-(tert-butoxycarbonyl) gemcitabine 
[Compound 2] (3.821 g, 8.2 mmol) was added to the stirred solution followed by 
diisopropylethylamine (5.82 mL, 41 mmol). The reaction mixture was stirred at 0 °C 
for 108 h under an argon atmosphere. The solvent was removed under reduced 
pressure to give a dark orange residue. Protected L-GEM [Compound 6] was obtained 
as a pale green powder (4.31 g, 62 % yield) after column chromatography using a 
mixture of 10:1 chloroform:methanol as eluent. Compound 6 1H NMR (SI-Figure 6):  
7.89 (singlet [14], 1H), 7.29 (doublet J=7.2Hz [13], 1H), 6.48 (br-singlet [5-endo], 
1H), 6.41 (br-singlet J=3.2Hz [5-exo], 1H), 6.27 (doublet J=4.2Hz [4-endo] 1H), 6.24 
(multiplet [17] 1H), 6.16 (multiplet [4-exo] 1H), 5.5 (br-singlet [3-endo], 1H), 5.20 
(br-singlet [12], 1H), 5.0 (br-singlet [3-exo], 1H), 4.45-4.31 (multiplet [10,11] 3H), 
3.44 (triplet J=14.3Hz [8], 2H), 3.40 (br-singlet [2-endo], 1H), 3.29 (doublet 
J=14.5Hz [6-endo], H), 2.97 (br-singlet [2-exo], 1H) 2.89 (doublet J=6.4Hz [6-exo], 
1H), 2.44 (triplet [9] 2H), 1.78 (triplet [7] 2H), 1.35 (doublet [16,18,19] 27H). 
 
Protected L-GEM [Compound 6] (4.31 g, 5.1 mmol) was dissolved in 185 mL of a 
solution of 15 % trifluoroacetic acid in dichloromethane (v/v) and the solution stirred 
at 0 °C for 2 h. The volatile solvents were removed under reduced pressure to give a 
dark red residue. L-GEM [Compound 7] was isolated as a pale orange powder (1.3 g, 
47 % yield) after column chromatography using a 1:1 mixture of 
acetone:dichloromethane as eluent. High resolution mass spectrometry of L-GEM 
was performed using a ThermoFisher Scientific LTQ Orbitrap XL hybrid ion trap-
orbitrap mass spectrometer. Samples were introduced to the spectrometer as solutions 
in dichloromethane/methanol with ammonium acetate added. All compounds 
analysed gave satisfactory data at high resolution as compared to predicted ionisation 
patterns. FTIR analysis was carried out using a Thermo Scientific Nicolet™ IS5 FTIR 
fitted with an attenuated total reflectance adapter (Thermofisher, UK). A background 
correction scan was carried out prior to sample analysis. A series of 64 scans 
(resolution = 4nm) were carried out and an average deduced. 
 
Retro Diels Alder linker breakdown at elevated temperatures  
The linker was heated in deuterated acetone in a round bottom flask at various 
temperatures. A 2 mL sample of the reaction mixture was added to a NMR tube, 
sealed with parafilm and cooled down by immersion into ice cold water for 5 min. 
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The samples were then analysed with 1H NMR spectroscopy (Bruker Avance 300 
MHz NMR Spectrometer, Bruker, Germany). Aliquot samples were analysed at the 0, 
5, 10, 15, 30, 60, 120 and 180 min mark and multiple round bottom flasks of the 
reaction mixture were heated to 37 °C, 45 °C and 70 °C in triplicate.  
 
Synthesis and characterization of hybrid nanoparticles (HNPs) 
Hybrid nanoparticle synthesis was carried out as previously reported [25,28,38]. 
Particles were analysed for their surface charge using a Malvern Zetasizer Nano ZS. 
The samples were analysed over 100 runs at 25 °C. TEM imaging was carried out 
using the JEOL JEM-1230 (JEOL, Japan) transmission electron microscope. Prior to 
imaging, formvar coated copper grids were prepared. The samples were pipetted (10 
µL) onto the grids and allowed to air dry before imaging. Inductively Coupled Plasma 
– Optical Emission Spectroscopy (ICP-OES) was used to measure the metal content 
of the HNPs. Samples were prepared first by adding 0.4 mL of suspended 
nanoparticles to a 2 mL solution of 1:1 hydrochloric acid/nitric acid (1:5 dilution of 
0.4 mL nanoparticles) which was gently heated for a few min until the nanoparticles 
were dissolved. The solutions were diluted in deionised water and analysed by an 
Agilent Technologies 700 series ICP-OES. The samples were compared to standard 
solutions in a calibration curve of Fe at 261.187 nm (R2 = 0.9997) and Au at 242.794 
nm (R2 = 0.9981) for gold. Uv-Vis spectroscopy characterization of HNPs was carried 
out using a Varian Cary 50 Bio Uv-Vis spectrophotometer over a wavelength range of 
400-700 nm in order to determine the maximum absorbance of the HNPs within this 
range.  
 
Preparation of HNP-L-GEM  
Into a sample tube, 5 mg of HNPs (based on iron mass) was added followed by 25 mg 
(based on gemcitabine mass) of the thiolated thermally labile drug (L-GEM). The 
mixture was diluted to 5 mL with deionised water and stirred for 2 h at room 
temperature. The HNP-L-GEM were magnetically separated and washed with 5 mL 
of deionised water. Total drug conjugation concentration was analysed using reverse 
phase HPLC. The peak area was used to calculate drug content from a calibrat ion 
curve (R2 = 0.999).  The HPLC system coupled to a UV detector used was a Perkin 
Elmer, Flexar LC,  Autosampler using a Pinnacle DB C18 reverse phase column. The 
flow rate for the solvent phase solution was 1 mL min-1 (1:1 v/v water:acetonitrile) for 
all samples unless otherwise stated and the sample injection amount is 10 μL. Sample 
fractions were analysed at 268 nm.  
 
In vitro drug release studies 
A dialysis membrane (12-14 kDa) was filled with 2 mL of HNP-L-GEM. The 
membrane was placed into 200 mL water or cell media at varied pH (7.4, 5.6) under 
sink conditions. The solutions were stirred and the rate of drug release measured at 
varied temperatures (20 ˚C, 37 ˚C & 44 ˚C). Aliquots (1 mL) of the solution were 
taken at various time points (1 min, 2 min, 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 3 
h, 4 h, 24 h, 48 h, 72 h and 96 h) and placed in HPLC vials. Fresh 1 mL of deionised 
water/cell culture media of appropriate pH was placed back into the conical flask. 
Total drug release was analysed using HPLC as described previously. Experiments 
were carried out in triplicate. 
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Stability assessment of formulation 
Vials containing HNP-L-GEM were stored at room temperature away from direct 
sunlight or refrigerated. Every seven days over a four-week period, the particulate 
formulations were magnetically separated from solution and a 0.1 mL aliquot from 
the supernatant of each vial was analysed using HPLC to calculate the amount of 
GEM that had released from the HNP surface.  HPLC was performed as previously 
described. Experiments were carried out in triplicate. 
 
In vitro evaluation 
All in vitro experiments and results discussed in this study were carried out using the 
BxPC-3 cells. Well plate cell cultures were produced by seeding BxPC-3 cells in their 
exponential growth phase and allowing them to incubate overnight at 37 °C within a 5 
% CO2 atmosphere in RPMI-1640 media supplemented with a 1 % streptomycin 
penicillin and 5 % foetal bovine serum [39]. 
 
Cytotoxicity measurement 
MTT assay  
A 96-well plate was seeded with 15,000 of BxPC-3 cells/well and incubated for 24 h. 
The media was removed and the well plates were dosed with HNPs, GEM, 
gemcitabine prodrug with the maleimide residue of the linker attached indicating 
where linker breakdown has occurred but linker has not dissociated from parent drug 
molecule (Mal-GEM), HNP-L-GEM (0.01 µg mL-1 – 100 µg mL-1), as well as 
mercaptofuran and HNP-mercaptofuran at the relative concentration on the particle 
surface (0.0042 µg mL-1 – 42 µg mL-1) in order to indicate toxicity after drug release 
had occurred. All samples were diluted in cell culture media containing 10% FBS and 
incubated for 24 h, 48 h or 72 h. Following this, the media and PBS was removed and 
replaced with a 175 μL solution of 10 % MTT in media. The plate was then incubated 
for 4 h, afterwards, the media was removed and 175 μL of DMSO was added. The 
UV absorbance of the plate was analysed at 570 nm using a Tecan Infinite M200 Pro 
Microplate Reader. Percentage cell viability was calculated in respect to positive and 
negative controls. Experiments were conducted in triplicates. 
 
Trypan blue exclusion assay 
Cells were seeded into a 12-well plate at 25,000 cells/well. The plate was incubated 
for 24 h. The media was removed and the BxPC-3 cells dosed with HNP, GEM, Mal-
GEM or HNP-L-GEM diluted in cell culture media containing 10% FBS (0.01 µg 
mL-1 – 100 µg mL-1). The plate was incubated for 24 h, 48 h or 72 h. Afterwards, the 
wells were washed three times with PBS and the cells were trypsinized (75 μL) and 
suspended in 0.5 mL of media [40]. Into a fresh Eppendorf tube 75 μL of trypan blue 
and 75 μL aliquot of cell suspension was added. The cells were counted using a 
Countess Invitrogen Automated Cell Counter (Invitrogen, UK) and the live cell 
counts were compared to those of the control to produce a percentage cell viability 
value for each sample concentration. Experiments were conducted in triplicate. 
 
Intracellular drug uptake  
Cells were seeded into 6-well plates at 50,000 cells/well. The plates were incubated 
for 24 h before media was removed. Cells were dosed with 50 μg mL-1 solution of 
HNP, GEM, Mal-Gem or HNP-L-GEM diluted in cell culture media containing 10% 
FBS. The cells were incubated for 1 h, 4 h or 24 h. Following this, the cell media was 
removed and the wells were washed three times with PBS. The cells were suspended 
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with 185 mL of trypsin before 0.815 mL of the media was added. The cells were then 
counted and 100,000 cells were placed into an Eppendorf tube. Deionised water was 
then added until the total volume of each tube was 1 mL. Centrifugation of this 
solution in a Hermule Z-323 centrifuge at 500 rpm for 5 min, drives the cell 
fragments to the bottom of the Eppendorf tube. The supernatant was removed and 
analysed via HPLC to determine drug content as previously described. The drug 
weight per cell was calculated. The experiment was carried out in triplicate. 
 
Effect of heat on cell viability  
The trypan blue assay was repeated with one alteration in method. After the cells had 
been dosed with the relevant formulation the incubation temperature was raised to 44 
°C over a period of 0.5 h in order for bulk solution to equilibrate (measured using thin 
wired thermocouples in a control well). The temperature was held at  44 °C  for 30 
sec, before returning back into the 37 °C, 50 % CO2 incubator [19]. The plates were 
further incubated for 48 h. The IC50 was determined for all 6 plates and the heat 
activated IC50 results were compared to the non-activated plates to note the effect on 
percentage cell viability. The experiments were carried out in triplicate. 
 
In vivo evaluation  
Female Nu/Nu mice, 4-5 wks old (Charles River, UK) were housed in pathogen-free 
conditions (weight of mice was 20–30 g). All procedures and animal care were 
carried out according to Project License PPL 70/8806 granted by the UK Home 
Office. 
 
Dose tolerability 
Healthy mice were injected intraperitoneal with HNPs (25 mg Kg-1) and Mal-GEM (6 
mg Kg-1) (n=2) once per week for 4 weeks. Mouse weight was recorded daily and 
monitored over the duration of the study as an indication of gross toxicity. 
 
Therapeutic Study 
Human pancreatic cancer cell line BxPC-3 was cultured to 90 % confluence in RPMI 
1640 media supplemented with 10 % fetal bovine serum and 1 % penicillin 
streptomycin. The cells were washed in PBS and trypsinized. The cells were washed 
with PBS, centrifuged at 800 rpm for 5 min and resuspended in 50:50 serum free 
media:PBS. The tumor cell suspension (3.0 X 106 cells in 100 L) was injected 
subcutaneously (s.c.) in the right flank of each mouse. When the tumor became 
palpable, measurements in two dimensions with vernier callipers were carried out 
twice a week and tumors volume calculated using V = 4/3π[(D1 + D2)/4]
3. Once 
tumors had reached 0.1 cm3 therapeutic studies commenced. The mice were grouped 
into 8 arms (n=5) of control, HNP, GEM, HNP-L-GEM all with and without laser 
irradiation. Drug administration was given at 3 mg Kg-1 with equivalent HNP 
concentration used in the HNP control. Doses were injected I.T. using a 26-gauge 
needle (Vet-Tech, UK) at a maximum of 100 L. The dose was administered one 
dose per wk over a 4 wk period. Where laser irradiation was required this was carried 
out 24 h after dosing under anaesthetic. The tumor was irradiated at 1064 nm for 20 
sec using a ML-LASER-YB5 Q-switched Nd:YAG Laser Treatment System 
(WeiFang MingLiang Electronics Company Ltd., China). Pulse width: 10 ns, pulse 
repetition frequency: 6 Hz, laser spot diameter: 3 mm, cooling system: water cooled 
with airflow cooling. The beam was collimated through concave lenses to a 1 mm 
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diameter. Any mouse whose tumor volume reached 0.9 cm3 was sacrificed in line 
with good practice guidelines [41].  
 
Statistical analysis 
A simple two tailed t-test was carried out to determine the statistical significance of 
results, whereby p0.01 was significant. 
 
 
Results and Discussion 
Synthesis of HNP-L-GEM 
Attachment of the thermally labile linker onto the gemcitabine molecule was achieved 
according to the general scheme shown in Figure 2. The identity of the final 
compound (L-GEM) was confirmed by NMR spectroscopy, Mass spectrometry and 
Fourier transform infrared spectroscopy. (SI-Figure 7). Analysis of L-GEM indicated 
the complete boc deprotection of the thiol and hydroxyl groups. Coincidentally a very 
strong garlic odour was detected from the compound which is a common trait 
amongst thiol compounds [42]. The HNPs were successfully synthesized, analysis of 
their synthetic pathway can be observed in Figure 3. Attachment of L-GEM onto the 
HNP surface occurred by dative covalent binding between the thiol residue in the 
linker moiety with the gold surface of the HNPs. The HPLC data showed that the 
gemcitabine analogue binding occurred (5 mg GEM:1 mg HNP) with 98 % 
efficiency. We can estimate how many furan-maleimide cycloadducts have been 
conjugated onto the HNP surface (1.13 X 1019 molecules per mg Fe), and therefore, 
once 100% release has occurred we can quantify the exact exposure (which equates to 
1.87 x 10-5 mol). 
 
The furan moiety is found in many delivery systems described in the literature which 
are based around a reversible furan-maleimide Diels-Alder reaction, of which most 
are polymer based [43]. These usually contain many furan residues (often regarded as 
toxic) in the parent polymer that is being loaded with the maleimide-conjugated drug. 
Reports have documented that not all furan conjugation sites are occupied after drug 
loading leaving the furan exposed in its native form [44]. In our HNP system, the 
Diels-Alder linkage is produced before drug conjugation, hence, no furan excess is 
required. For these particles, this concentration is far lower than that of the reported 
polymers. These furans are conjugated onto the HNP via dative covalent binding, 
which will only breakdown at temperatures far above our target temperature. Hence, 
any metabolites produced will remain attached to the HNP and remain localised to the 
tumor. 
 
Due to the high level of loading, it is likely that the HNP surface was not saturated 
and that higher loading quantities may have been achievable at higher drug:HNP feed 
ratios.  
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Figure 2. Reaction scheme for the synthesis of the Diels Alder cycloadduct formation and 
conjugation onto gemcitabine forming L-GEM [Compound 7]. 
 
 
 
Figure 3. Physical characterization of nanoparticles using A) TEM 1. Uncoated iron oxide, 
2. PEI coated iron oxide, 3. Gold seeds attached to PEI coated iron oxide and 4. HNPs. B) 
UV-Vis spectroscopy scanning between 400 nm – 700 nm. C) Zeta potential measurement 
carried out in water at room temperature. 
 
In vitro drug release studies 
Drug release occurs in this system when a threshold temperature is met or exceeded 
which is resultant from laser irradiation. Here we purposefully designed a system 
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which would release at approximately 44 ºC in order to allow drug release to occur 
below the temperatures which would result in cellular ablation.  
The released drug compound will have a maleimide chain attached onto it, differing 
in structure to the native GEM molecule. Hence, the released compound will be called 
Mal-GEM. Drug release at increasing temperature was carried out at pH 7 (water), pH 
5.6 (cell media) and pH 7.4 (cell media). The pH’s were chosen due to their biological 
relevance. Figure 4A shows the percentage release of detected Mal-GEM over time 
from the HNP-L-GEM in water, pH 7. At 20 ˚C in there is negligible Mal-GEM 
release over the time period tested (P < 0.05).  
 
 
 
 
Figure 4. Evaluation of HNP-L-GEM. A) In vitro drug release carried out at varied 
temperatures in water and B) Stability of formulation stored in the fridge and at room 
temperature over 4 weeks (n=3, ±SD). * denotes significance compared with 20 ºC and # 
compared with all other temperatures tested (p<0.01). 
 
This trend was also observed at pH 7.4 and pH 5.6 (SI-Figure 9). Drug release was 
also carried out at 37 °C in order to mimic what may happen at body temperature. At 
pH 7, the HNP-L-GEM formulation showed a time dependant release. There was an 
initial burst release where 13 % of the GEM was released within 60 sec, after which 
no further release was observed (Figure 4A). The initial burst release of Mal-GEM 
from HNP-L-GEM at pH 7.4 (SI-Figure 9A) and pH 5.6 (SI-Figure 9B) at 37 °C was 
13 % and 14 % respectively. Mal-GEM release was analysed at 44 °C, this 
temperature was used to mimic the temperature of HNPs after laser irradiation. These 
studies were carried out at varied pH (7, 7.4, & 5.6 as previously discussed). Figure 
4A confirms that at this elevated temperature, a rapid and significantly increased 
release of Mal-GEM from the HNP-L-GEM was observed.  At pH 7, 80 % of the 
Mal-GEM had been released after only 60 sec. At a pH of 7.4 (SI-Figure 9A) 80 % of 
Mal-GEM was released with 81 % being released at pH 5.6 (SI-Figure 9B) after 60 
sec. 
 
This large increase in release rate is in agreement with in-depth modelling and 
experimental study into the kinetics of the Diels Alder reaction and the corresponding 
retro Diels Alder reaction of 2-substituted furans with N-alkylated maleimides [45]. 
Froidevaux et al. reported that for a 10 ºC increase in temperature they observed 
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almost a 5 x increase in the rate of the retro Diels Alder reaction, using cycloadducts 
similar to the one used in our linker [45].  
Our findings confirm that temperature is the major factor which influences the 
induction of retro Diels Alder reaction and hence liberation of Mal-GEM molecules. 
Hence, these systems have potential as thermally triggered drug delivery vehicles 
 
Stability assessment of formulation 
The data in Figure 4B shows negligible drug dissociation at both 20 °C and 5 °C (p 
<0.01). Hence, it can be deduced that storage of the formulations would result in 
stable systems over a 4-week period. In comparison with other thermally responsive 
drug delivery systems for the transport and release of GEM this stability profile is 
exciting. The use of magnetoliposomes to encapsulate gemcitabine has been shown to 
only have a stable lifespan of 4 days determined by dynamic light scattering, before 
aggregation and drug release occurs [46]. this is a much shorter potential shelf life 
than the 4 weeks of high stability shown for the HNP-L-GEM.  
 
In vitro evaluation 
The Mal-GEM released from the HNP is a prodrug. In order for gemcitabine to 
become liberated (for activity), the maleimide linker must be cleaved from the 
primary amine of gemcitabine. Such prodrugs are well documented [47]. In order for 
activity to be observed, the amide bond in the prodrug will be cleaved via hydrolysis, 
especially if taken up by endocytosis, or by enzymatic pathways. 
The cytotoxic effect of GEM, HNP, Mal-GEM and the HNP-L-GEM formulation 
were observed in BxPC-3 cells over 72 h. Data from the MTT assays showed that the 
only compound exhibiting an IC50 value after 24 h was Mal-GEM (38 µg mL
-1) (SI-
Table 1), whilst all the other compounds remained relatively non-toxic over the 
concentration ranges tested. The GEM and HNP-L-GEM did not exhibit IC50 values 
until after 48 h incubation (SI-Table1) with the lowest IC50 values observed after 72 h 
(Figure 5A). Data obtained from trypan blue exclusion is slightly different than that 
obtained from the MTT assay. Overall the IC50 values are lower when calculated via 
the MTT assay compared to the trypan blue exclusion assay. The main reason for this 
is that the MTT assay merely estimates the number of living cells based on their 
ability to metabolise MTT into formazan crystals and compares this activity to 
controls. The trypan blue exclusion assay will display a positive result for living cells, 
even if their metabolic processes have been reduced and hence, may give a better 
indication of actual cellular state. The data obtained using trypan blue exclusion 
consistently showed that no IC50 value was present after 24 h for all the particulates 
and drugs tested, with 50 % cell growth inhibition only observed after 48 h (SI-Table 
1).  
 
Overall the in vitro evaluation of Mal-GEM showed that that modification of the 
GEM molecule to include the linker had an impact on its overall toxicity. The IC50 of 
Mal-GEM after 48 h was 75 µg mL-1 (SI-Table 1) which was 4.3-fold higher than for 
GEM (17.5 µg mL-1) which decreased to a 2.5–fold increase after 72 h (Figure 5B). 
However, after conjugation onto the HNP surface, the IC50 values observed after 48 h 
were comparable to that of the free GEM. This phenomenon, is not thought to be due 
to inherent toxicity of the HNPs, but due to the uptake mechanism of the 
drug/formulations. Figure 5C shows the cellular uptake in BxPC-3 cells measured up 
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to 24 h. In this study, GEM and Mal-GEM show similar intracellular drug levels at all 
time points which suggests that Mal-GEM enters the cell via similar mechanisms to 
the native drug molecule. It is likely that both the free drug and prodrug enter via the 
tight junction in the cell membrane which can be a time-consuming process, as well 
as being actively transported across the cell membrane with SLC28 and SLC29 
nucleoside transporters [48,49]. Here it is clear to see, that after conjugation onto the 
nanoparticle surface a significant increase in cellular internalisation of drug is 
achieved (P < 0.05). Hence this would indicate that the cellular trafficking mechanism 
of the HNP-L-GEM is different compared with the drug and prodrug. Numerous 
studies have indicated that nanoparticulate vehicles enter cells via endocytosis. This is 
often relatively rapid and results in much higher intracellular concentrations. Hence, 
greater levels of drug are entering the cell which accounts for the IC50 decrease 
compared to the Mal-GEM.  
 
 
Figure 5. In vitro cellular evaluation of the novel HNP-L-GEM formulation carried out on 
human pancreatic adenocarcinoma (BxPC-3) cells. Cytotoxicity measured by A) MTT assay 
and B) Trypan blue exclusion after 72 h exposure *denotes significance reduction in cell 
viability, # denotes significant reduction in viability compared to GEM (p<0.01). C) 
Cellular uptake of HNP-L-GEM at 1 h, 4 h and 24 h. *denotes significant increase compared 
with 1 h. D) Change in IC50 value after heat activation of HNP-L-GEM at 44 ºC for 30 min 
and incubation for 48 h measured via Trypan blue exclusion. *denotes significance 
reduction in IC50 compared with non-heat activated sample, # denotes significant 
reduction in viability compared to GEM (p<0.01). For all experiments (n=3, ±SD). 
 
It is acknowledged that all nanoparticle internalisation studies may contain some bias 
due to nanoparticles sticking to the cellular membrane externally being included 
within the analysis. This work uses reported assay in which each sample is washed 
multiple times before analysis in order to limit such bias [19]. In addition, due to the 
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final surface charge of the HNP-L-GEM ( -2.6 mV) it is unlikely that they will stick 
onto the negatively charged cell membrane with great affinity and hence bias should 
be minimised. 
 
The thermo-responsive nature of the HNP-L-GEM indicates that after heat activation 
(at 44 °C as determined via drug release) the immobilised Mal-GEM will be released 
from the surface of the HNP resulting in freely available drug to the ce ll. We 
postulated that this would result in a further increase in cytotoxic effect. Hence, a 
study was carried out which incubated the HNP-L-GEM with BxPC-3 cells for 24 h 
to ensure cellular uptake had occurred. The cells were then exposed to the elevated 
temperature of 44 °C for 0.5 h, before returning back to 37 °C for 24 h. The IC50 
values both before and after heat activation are displayed in Figure 5D. As observed 
in the previous cytotoxicity studies, no IC50 was present for the HNPs. The GEM and 
Mal-GEM did not experience any significant change in their IC50 values after heat 
activation. However, the HNP-L-GEM experienced a 56 % increase in cytotoxicity 
after heating compared with no activation. This significant (p<0.01) reduction 
indicates that once heat activated the HNP-L-GEM undergoes retro Diels Alder 
reaction liberating Mal- GEM which results in a greater degree of toxicity compared 
to the immobilised inactivated HNP-L-GEM. This was expected as the rate of the 
retro Diels Alder reaction was shown to increase at increased temperatures. 
Additionally, the heat activated HNP-L-GEM resulted in a 26 % improvement in 
cytotoxicity compared to the free GEM.  
 
Ideally the non-heat activated HNP-L-GEM would have remained non-toxic until heat 
activation had occurred. However, it is evident from the cell based assays that this is 
not the case. However, it may be possible to protect the drugs bound onto the surface 
of the HNPs using long chain polymers which will hinder the drug activity until 
liberated by heat. 
 
Additional toxicity assays were carried out on the furan moiety (equivalent to those 
concentrations of gemcitabine reported) both before and after conjugation onto the 
HNP system at the specific binding concentration (SI-Figure 10). These studies 
showed, that there was no observable significant toxicity over 24 h and 48 h, with a 
slight toxic effect observed after 72 h. The biological toxicity from furans can be 
attributed to the metabolite: Z-2-butene-1,4-dial which contains two aldehyde 
functional groups in conjugation with a bridging C=C double bond. The conversion of 
furan into its metabolite form is catalysed by a cytochrome P450. In systemic 
circulation this may be problematic, especially in the liver. However, this formulation 
is being administered I.T., hence, two factors will contribute to the reduction of 
metabolism into the toxic form. These are: 1) there is a much-reduced presence of the 
catalyst enzyme P450 in pancreatic tumors and 2) the tumor microenvironment is 
hypoxic and hence probability of conversion is lower than would be for systemic 
metabolism. Currently, this is under study within our laboratories. Additionally, 
pancreatic tumors are extremely dense and solid and hence, leakage into systemic 
circulation is highly unlikely.  
 
In vivo evaluation 
In vivo therapeutic studies were carried out in BxPC-3 xenograft tumors grown 
subcutaneous in nude mice. Before study commencement a dose toxicity study was 
carried out in healthy mice to ensure no gross toxicity would occur. These findings 
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(SI-Figure 11) showed that mice maintained their body weight and continued to grow 
over the study duration after administration of the HNPs and Mal-GEM.  
 
Figure 6A shows the tumor volume measurements taken throughout the duration of 
the therapeutic study with the various treatment regimes. Those mice in the control 
and HNP groups both with and without laser irradiation did not last the duration of the 
study, due to their tumor volumes approaching the maximum humane limit as set out 
by the UK Home office. Figure 6B shows the excised tumors at the end of the study. 
In agreement with the tumor volume data it is observed that there is no significant 
difference in tumor size after HNP treatment (Figure 6B3) compared with the control 
(Figure 6B1). Likewise, there does not appear to be any effect on tumor volume or 
weight (Figure 6C) resulting from laser irradiation which can be observed in the 
control group with PBS treatment Figure 6B1&2 and also after HNP treatment 
(Figure 6B3&4).  
 
 
Figure 6. In vivo evaluation on BxPC-3 xenograft models in Nu/Nu female mice (4-6 weeks 
old) dosed once a week at 3 mgKg
-1
 for 4 weeks. A) Comparison of tumor volume over study 
duration ∞ Study stopped before completion due to tumor volume approaching maximum 
humane volume (0.9 cm
3
). B) Comparison of tumors after excision: 1) control, 2) control with 
laser irradiation, 3) HNP, 4) HNP with laser irradiation, 5) GEM, 6) GEM with laser 
irradiation, 7) HNP-L-GEM, 8) HNP-L-GEM with laser irradiation. Where laser irradiation 
was required this was carried out 24 h after dosing under anaesthetic. The tumor was 
irradiated at 1064 nm as for 20 sec using a ML-LASER-YB5 Q-switched Nd:YAG Laser 
Treatment System. Pulse width: 10 ns, pulse repetition frequency: 6 Hz, laser spot diameter: 
3 mm, cooling system: water cooled with airflow cooling. The beam was collimated through 
concave lenses to a 1 mm diameter. C) Comparison of tumor weight after excision * denotes 
significance compared to controls, ** denotes significance compared to GEM, *** denotes 
significance compared to HNP-L-GEM without laser irradiation (p<0.01) (n=5, ±SE). 
 
 
As expected, those mice treated with GEM did experience significant tumor 
retardation (p<0.01) compared to the control groups as evident in the tumor volume 
and weight measurements (Figure 6). Again, the irradiation for 20 sec at 1064 nm did 
not have any impact on the tumor growth. Those mice treated with HNP-L-GEM did 
incur tumor retardation without laser irradiation. The tumors reduced in line with the 
GEM group with no significant increase or decrease in tumor weight or volume 
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observed. However, after laser irradiation a significant decrease in tumor volume 
(Figure 6A) and weight (Figure 6C) was observed, this was confirmed on excision of 
the tumors where it can clearly be seen that the tumors which underwent laser 
irradiation is visibly smaller than that of the non- irradiated group (Figure 6B). In fact, 
a 4.4–fold decrease in tumor weight compared to the control group and 1.6–fold 
decrease compared to the GEM was observed.  
 
These exciting findings support the in vitro findings and indicate that once coupled 
onto the HNP it is likely that greater cellular internalisation of drug is occ urring and 
that the retro Diels Alder reaction triggered by laser irradiation is liberating Mal-GEM 
which results in a greater effect compared to the GEM alone. 
 
Conclusion  
This study evaluates the use of linkages prepared by the Diels Alder reaction to 
reversibly bind gemcitabine onto the surface of HNPs for exploitation as a possible 
treatment in pancreatic cancer. This is the first report of a metallic nanoparticle 
delivery system for the transport and thermal release of GEM which utilizes chemical 
reactions rather than physical changes to elicit a controllable temperature dependant 
drug release. The novel formulation (HNP-L-GEM) produced was capable of high 
drug loading which appeared stable even upon reduction of pH. At elevated 
temperatures, the retro Diels Alder breakdown of the ligand occurred and resulted in 
rapid liberation of the prodrug. In vitro studies suggested that the prodrug itself was 
less toxic than free GEM, however after coupling onto the HNP rapid cellular 
internalisation occurred which resulted in 26 % reduction in cell viability compared 
with GEM after heat activation. The in vivo studies confirmed that heat activation of 
the HNP-L-GEM in BxPC-3 xenografts resulted in 62 % reduction in tumor weight 
compared with GEM.  
 
These exciting results demonstrate the potential of the HNP-L-GEM formulation as a 
possible replacement to gemcitabine as a first line treatment for pancreatic cancer. 
However, in order for this formulation to be further optimised, further studies are 
being carried out to create to a second-generation system with addition of specific 
targeting peptides in order to encourage preferential uptake into the cancerous cells 
whilst evading the fibroblast cells. Furthermore, the clinical potential of this platform 
is not limited to mono drug therapy or indeed pancreatic cancer treatment, it would be 
possible to offer combined treatment regimens using multiple prodrugs attached to the 
HNP surface for any diseased state requiring controllable release of drug molecules.   
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